• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Michael Schnekenburger, Cindy Grandjenette, +4 authors Marc F Diederich
  • Chemistry, Medicine
  • Biochemical pharmacology
  • 2011 (First Publication: 1 February 2011)
  • In addition to its demethylating properties, 2'-deoxy-5-azacytidine (DAC) induces cell cycle arrest, differentiation, cell sensitization to chemotherapy, and cell death. However, the mechanisms byExpand
  • Cristina Florean, Michael Schnekenburger, +13 authors Marc F Diederich
  • Biology, Medicine
  • Oncotarget
  • 2016 (First Publication: 19 March 2016)
  • We characterized the brominated alkaloid Isofistularin-3 (Iso-3), from the marine sponge Aplysina aerophoba, as a new DNA methyltransferase (DNMT)1 inhibitor. Docking analysis confirmed our in vitroExpand
  • Cindy Grandjenette, Michael Schnekenburger, +5 authors Marc F Diederich
  • Biology, Medicine
  • Neoplasia
  • 2014 (First Publication: 1 June 2014)
  • Increased proliferation rates as well as resistance to apoptosis are considered major obstacles for the treatment of patients with chronic myelogenous leukemia (CML), thus highlighting the need forExpand
  • Dante Rotili, Domenico Tarantino, +16 authors Antonello Mai
  • Biology, Medicine
  • PloS one
  • 2014 (First Publication: 8 May 2014)
  • Chemical manipulations performed on the histone H3 lysine 9 methyltransferases (G9a/GLP) inhibitor BIX-01294 afforded novel desmethoxyquinazolines able to inhibit the DNA methyltransferase DNMT3A atExpand
  • Anne Trécul, Franck Morceau, +5 authors Marc F Diederich
  • Medicine, Biology
  • Cancer letters
  • 2013 (First Publication: 28 October 2013)
  • Constitutive activity of kinases has been reported in many types of cancers, so that inhibition of "onco-kinases" became a validated anti-cancer strategy. We found that the polyphenol 13c, aExpand
  • Cindy Grandjenette, Michael Schnekenburger, +5 authors Marc F Diederich
  • Medicine, Biology
  • Anti-cancer agents in medicinal chemistry
  • 2015 (First Publication: 28 February 2015)
  • Despite recent advances in the treatment of chronic myelogenous leukemia (CML), the development of drug resistance and minimal residual disease remain major challenges for the treatment of CMLExpand
  • Cindy Grandjenette, Michael Schnekenburger, +5 authors Marc F Diederich
  • Biology, Medicine
  • Cancer letters
  • 2019 (First Publication: 14 November 2019)
  • Although tyrosine kinase inhibitors (TKI) revolutionized the management of chronic myeloid leukemia (CML), resistance against TKIs and leukemia stem cell (LSC) persistence remain a clinical concern.Expand